open access

Vol 87, No 3 (2019)
REVIEWS
Published online: 2019-06-28
Submitted: 2019-03-17
Accepted: 2019-05-18
Get Citation

Is inhaled heparin a viable therapeutic option in inhalation injury?

Michał Zieliński, Piotr Wróblewski, Jerzy Kozielski
DOI: 10.5603/ARM.2019.0029
·
Pubmed: 31282560
·
Adv Respir Med 2019;87(3):184-188.

open access

Vol 87, No 3 (2019)
REVIEWS
Published online: 2019-06-28
Submitted: 2019-03-17
Accepted: 2019-05-18

Abstract

Inhalation injury is a major cause of morbidity and mortality in patients with burns. Presence of airways injury adds to the need of fluid supplementation, increases risk of pulmonary complications. Due to many mechanisms involved in pathophysiology the treatment is complex. Among them the formation of fibrin casts inside airways constitutes a prominent element. The material residing in tracheobronchial tree causes ventilation-perfusion mismatch, complicates mechanical ventilation, provides a medium for bacterial growth. Many studies of animal models and single centre human studies investigated inhaled anticoagulation regimens employing heparin in management of inhalation injury. Simultaneously safety, especially in connection with possible bleeding risk, was the subject of research. The results suggest positive impact on treatment results, with low risk of side effects. This paper revise the available clinical data on inhaled heparin use in patients with burns.

Abstract

Inhalation injury is a major cause of morbidity and mortality in patients with burns. Presence of airways injury adds to the need of fluid supplementation, increases risk of pulmonary complications. Due to many mechanisms involved in pathophysiology the treatment is complex. Among them the formation of fibrin casts inside airways constitutes a prominent element. The material residing in tracheobronchial tree causes ventilation-perfusion mismatch, complicates mechanical ventilation, provides a medium for bacterial growth. Many studies of animal models and single centre human studies investigated inhaled anticoagulation regimens employing heparin in management of inhalation injury. Simultaneously safety, especially in connection with possible bleeding risk, was the subject of research. The results suggest positive impact on treatment results, with low risk of side effects. This paper revise the available clinical data on inhaled heparin use in patients with burns.

Get Citation

Keywords

inhalation injury; inhaled heparin; burn

About this article
Title

Is inhaled heparin a viable therapeutic option in inhalation injury?

Journal

Advances in Respiratory Medicine

Issue

Vol 87, No 3 (2019)

Pages

184-188

Published online

2019-06-28

DOI

10.5603/ARM.2019.0029

Pubmed

31282560

Bibliographic record

Adv Respir Med 2019;87(3):184-188.

Keywords

inhalation injury
inhaled heparin
burn

Authors

Michał Zieliński
Piotr Wróblewski
Jerzy Kozielski

References (45)
  1. AbdelWahab ME, Sadaka MS, Elbana EA, et al. Evaluation of prognostic factors affecting lenght of stay in hospital and mortality rates in acute burn patients. Ann Burns Fire Disasters. 2018; 31(2): 83–88.
  2. Güldoğan CE, Kendirci M, Gündoğdu E, et al. Analysis of factors associated with mortality in major burn patients. Turk J Surg. 2018 [Epub ahead of print]: 1–8.
  3. Gupta K, Mehrotra M, Kumar P, et al. Smoke Inhalation Injury: Etiopathogenesis, Diagnosis, and Management. Indian J Crit Care Med. 2018; 22(3): 180–188.
  4. Veeravagu A, Yoon BC, Jiang B, et al. National trends in burn and inhalation injury in burn patients: results of analysis of the nationwide inpatient sample database. J Burn Care Res. 2015; 36(2): 258–265.
  5. Miller AC, Elamin EM, Suffredini AF, et al. Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review. Crit Care Med. 2014; 42(2): 413–419.
  6. Cheng W, Yan-hua R, Fang-gang N, et al. Epidemiology of 1974 burn patients at a major burn center in Beijing: a nine-year study. J Burn Care Res. 2012; 33(5): e228–e233.
  7. Tian H, Wang L, Xie W, et al. Epidemiologic and clinical characteristics of severe burn patients: results of a retrospective multicenter study in China, 2011-2015. Burns Trauma. 2018; 6: 14.
  8. Lipový B, Fiamoli M, Gregorová N, et al. Epidemiology of critical burns in southern Moravia. Acta Chir Orthop Traumatol Cech. 2012; 79(4): 370–375.
  9. Theodorou P, Xu W, Weinand C, et al. Incidence and treatment of burns: a twenty-year experience from a single center in Germany. Burns. 2013; 39(1): 49–54.
  10. Dhopte A, Tiwari VK, Patel P, et al. Epidemiology of pediatric burns and future prevention strategies-a study of 475 patients from a high-volume burn center in North India. Burns Trauma. 2017; 5: 1.
  11. Saeman MR, Hodgman EI, Burris A, et al. Epidemiology and outcomes of pediatric burns over 35 years at Parkland Hospital. Burns. 2016; 42(1): 202–208.
  12. Chrzanowska-Wąsik M, Chemperek E, Sokołowski D, et al. Burn analysis in adult patients hospitalized in the east centre of burn treatment and reconstructive surgery in Łęczna. Zenodo. 2017.
  13. Matuszczak E, Dębek W, Chomicz A, et al. Analiza etiologii i epidemiologii oraz ocena wyników leczenia oparzeń u dzieci. Pediatria Polska. 2011; 86(3): 254–259.
  14. Dries DJ, Dries DJ. Management of burn injuries--recent developments in resuscitation, infection control and outcomes research. Scand J Trauma Resusc Emerg Med. 2009; 17: 14.
  15. Albright JM, Davis CS, Bird MD, et al. The acute pulmonary inflammatory response to the graded severity of smoke inhalation injury. Crit Care Med. 2012; 40(4): 1113–1121.
  16. Lange M, Enkhbaatar P, Traber DL, et al. Role of calcitonin gene-related peptide (CGRP) in ovine burn and smoke inhalation injury. J Appl Physiol (1985). 2009; 107(1): 176–184.
  17. Stothert JC, Ashley KD, Kramer GC, et al. Intrapulmonary distribution of bronchial blood flow after moderate smoke inhalation. J Appl Physiol (1985). 1990; 69(5): 1734–1739.
  18. Cox RA, Mlcak RP, Chinkes DL, et al. Upper airway mucus deposition in lung tissue of burn trauma victims. Shock. 2008; 29(3): 356–361.
  19. Maybauer MO, Rehberg S, Traber DL, et al. [Pathophysiology of acute lung injury in severe burn and smoke inhalation injury]. Anaesthesist. 2009; 58(8): 805–812.
  20. Cox RA, Burke AS, Soejima K, et al. Airway obstruction in sheep with burn and smoke inhalation injuries. Am J Respir Cell Mol Biol. 2003; 29(3 Pt 1): 295–302.
  21. Lange M, Hamahata A, Enkhbaatar P, et al. Pathophysiology of acute lung injury in combined burn and smoke inhalation injury. Clin Sci (Lond). 2004; 107(2): 137–143.
  22. Seeger W, Stöhr G, Wolf HR, et al. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol (1985). 1985; 58(2): 326–338.
  23. Dai NT, Chen TM, Cheng TY, et al. The comparison of early fluid therapy in extensive flame burns between inhalation and noninhalation injuries. Burns. 1998; 24(7): 671–675.
  24. Navar PD, Saffle JR, Warden GD, et al. Effect of inhalation injury on fluid resuscitation requirements after thermal injury. Am J Surg. 1985; 150(6): 716–720.
  25. de La Cal MA, Cerdá E, García-Hierro P, et al. Pneumonia in patients with severe burns : a classification according to the concept of the carrier state. Chest. 2001; 119(4): 1160–1165.
  26. Molitoris U, Vogt PM, Raymondos K, et al. Inhalation injury. Respiratory Emergencies. 2006: 64–83.
  27. Enkhbaatar P, Cox RA, Traber LD, et al. Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. Crit Care Med. 2007; 35(12): 2805–2810.
  28. Tasaki O, Mozingo DW, Dubick MA, et al. Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model. Crit Care Med. 2002; 30(3): 637–643.
  29. Cindrick L, Schenarts P, Bone H, et al. Nebulization of a non-anticoagulant heparinoid (gm1892) attenuates lung lymph flow after acute lung injury in sheep. FASEB J 1996;10; https://nebraska pure elsevier com/en/publications/nebulization-of-a-non-anticoagulant-heparinoid-gm1892-attenuates [accessed: 16 Jan 2019].
  30. Katahira J, Murakami K, Mlcak R, et al. Effect of heparin nebulization in burn and smoke inhalation injury in sheep. Shock. 2001; 15(Supplement): 6.
  31. Desai MH, Mlcak R, Richardson J, et al. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine [correction of acetylcystine] therapy. J Burn Care Rehabil. 1998; 19(3): 210–212.
  32. Holt J, Saffle JR, Morris SE, et al. Use of inhaled heparin/N-acetylcystine in inhalation injury: does it help? J Burn Care Res. 2008; 29(1): 192–195.
  33. Rivero A, Elamin E, Nguyen Vu, et al. Can nebulized heparin and n-acetylcysteine reduce acute lung injury after inhalation lung insult? Chest. 2007; 132(4).
  34. Murray JF, Matthay MA, Luce JM, et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988; 138(3): 720–723.
  35. Miller AC, Rivero A, Ziad S, et al. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res. 2009; 30(2): 249–256.
  36. Trial of nebulized heparin versus placebo for inhalation trauma — full text view clinicaltrials.gov. https://clinicaltrials gov/ct2/show/NCT01773083 [accessed: 18 Jan 2019].
  37. Elsharnouby NM, Eid HEA, Abou Elezz NF, et al. Heparin/N-acetylcysteine: an adjuvant in the management of burn inhalation injury: a study of different doses. J Crit Care. 2014; 29(1): 182.e1–182.e4.
  38. Kashefi NS, Nathan JI, Dissanaike S, et al. Does a nebulized heparin/N-acetylcysteine protocol improve outcomes in adult smoke inhalation? Plast Reconstr Surg Glob Open. 2014; 2(6): e165.
  39. McIntire AM, Harris SA, Whitten JA, et al. Outcomes following the use of nebulized heparin for inhalation injury (HIHI Study). J Burn Care Res. 2017; 38(1): 45–52.
  40. Chopra A, Burkey B, Calaman S, et al. A case report of clinically significant coagulopathy associated with aerosolized heparin and acetylcysteine therapy for inhalation injury. Burns. 2011; 37(7): e73–e75.
  41. Bendstrup KE, Gram J, Jensen JI, et al. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. Eur Respir J. 2002; 19(4): 606–610.
  42. Yip LY, Lim YF, Chan HN, et al. Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital Burns Centre. Burns. 2011; 37(7): 1154–1160.
  43. Dixon B, Santamaria JD, Campbell DJ, et al. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care. 2008; 12(3): R64.
  44. Dixon B, Schultz MJ, Smith R, et al. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care. 2010; 14(5): R180.
  45. Dixon B, Smith R, Santamaria JD, et al. A trial of nebulised heparin to limit lung injury following cardiac surgery. Anaesth Intensive Care. 2016; 44(1): 28–33.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl